CAS: 101530-10-3; Lanoconazole

该化合物是主要用于治疗表面真菌感染的抗风素剂,属于非伊迪佐尔衍生物类别,并展示了针对各种皮肤素和酵母的广泛抗风素活动.lanoconazole的化学结构具有三氮环特征,这对它的行动机制至关重要,因为它抑制了酶拉诺斯特罗14-demophyase,干扰了真菌细胞膜中的异地醇合成.这种干扰导致膜渗透性增加,最终导致细胞死亡.拉诺康那州通常在专题上管理,以最小的系统吸收方式对局部感染有效.它的相形色色素特征表明毒性相对较低,有助于其临床安全使用.此外,拉诺康那州在治疗诸如锡纳,开氏线和其他皮肤菌感染方面表现出了功效.它的配方可能包括奶油,乳液或溶液,允许在感染地点进行多功能性应用.

结构式图片

欧盟法规

C&L通报

上下游产品

potassium hydroxide 1-cyanomethylimidazole

合成工艺路线路线简述

    专利信息


    专利号:US-7199128-B2
    优先权日:2005-02-02
    标题 :8-N-substituted-2H-isothiazolo[5,4-b]quinolizine-3,4-diones and related compounds as antiinfective agents
    发明人:BRADBURY BARTON J; WILES JASON ALLAN; DESHPANDE MILIND; WANG QIUPING; HASHIMOTO AKIHIRO; LUCIEN EDLAINE
    权利人:ACHILLION PHARMACEUTICALS INC
    摘要:The invention provides compounds and salts of Formula I and Formula II: n nwhich possess antimicrobial activity. The invention also provides novel synthetic intermediates useful in making compounds of Formula I and Formula II. The variables A 1 , A 8 , R 2 , R 3 , R 5 , R 6 , R 7 , and R 9 are defined herein.n n Certain compounds of Formula I and Formula II disclosed herein are potent and selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula I or Formula II as the only active agent or may contain a combination of compounds of Formula I and/or Formula II and one or more other active agents. The invention also provides methods for treating microbial and protozoal infections in animals.

    专利号:US-8361516-B2
    优先权日:2006-08-03
    标 题:Composition comprising sarsasapogenin
    发明人:LINTNER KARL; MAS CHAMBERLIN CLAIRE
    权利人:SEDERMA SA; LINTNER KARL; MAS CHAMBERLIN CLAIRE
    摘要:The présent invention relates to a composition comprising sarsasapogenin or a plant extract containing it in order to improve the gêneral state of the skin and in particular to improve and/or embellish any part of the body showing a déficit in lipids. More particularly, the invention is directed to a cosmetic method to improve the figure, comprising the step of topically applying to the skin a cosmetic or dermopharmaceutical composition comprising sarsasapogenin to favour the expansion and/or the formation of the subcutaneous adipose tissue, and/or to favour the lipid synthesis in the epidermis.

    专利号:US-2014315720-A1
    优先权日:2012-10-24
    标 题 :Polysaccharide ester microspheres and methods and articles relating thereto
    发明人:FALLON DENIS G; GARRETT THOMAS S; KIZER LAWTON E; ZAZZARA KAREN L; COMBS MICHAEL T; JOHNSON RICHARD K; DEHART GARY
    权利人:CELANESE ACETATE LLC
    摘要:A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a polysaccharide synthesis, wherein the polysaccharide ester product comprises a polysaccharide ester and a solvent; diluting the polysaccharide ester product, thereby yielding a polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide ester dope. Suitable polysaccharides may include, but are not limited to, starch, cellulose, hemicellulose, algenates, chitosan, and any combination thereof. Esters thereof may be organic esters (e.g., acetate and the like), inorganic esters (e.g., sulfonates and the like), or combinations thereof. Further, the solids conent of the polysaccharide ester dope, in some instances, may be greater than about 16 wt %.

    专利号:RU-2189982-C2
    优先权日:1997-03-31
    标题:Azole compounds, method of their synthesis, antifungal pharmaceutical composition and method of treatment of fungal infection

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Uratsuji H, Nakamura A, Yamada Y, Hashimoto K, Matsumoto T, Ikeda F, Ishii R. Anti-inflammatory activity of lanoconazole, a topical antifungal agent. Mycoses. 2015 Apr;58(4):197-202. doi: 10.1111/myc.12297. Epub 2015 Feb 10. doi: 10.1128/AAC.01193-16. Print 2016 Nov.
    3: Ghannoum MA, Long L, Kim HG, Cirino AJ, Miller AR, Mallefet P. Efficacy of terbinafine compared to lanoconazole and luliconazole in the topical treatment of dermatophytosis in a guinea pig model. Med Mycol. 2010 May;48(3):491-7. doi: 10.3109/13693780903373811. doi: 10.1111/j.1439-0507.2009.01723.x. Epub 2009 May 5. doi: 10.1093/mmy/myw016. Epub 2016 Apr 26. doi: 10.1016/j.jpba.2009.05.004. Epub 2009 May 15. Japanese. Japanese.
    18: Niwano Y, Ohmi T, Kanai K, Hamaguchi H, Uchida K, Yamaguchi H. [In vitro antifungal activities of lanoconazole against stock cultures and clinical isolates of Candida albicans]. Jpn J Antibiot. 1995 Jan;48(1):140-5. Japanese. Japanese.

    合成参考文献


    参考文献:10.1007/s11046-015-9954-6
    摘要:Falahati M, Ghojoghi A, Abastabar M, Ghasemi Z, Farahyar S, Roudbary M, Hedayati MT, Armaki MT, Hoseinnejad A. The First Case of Total Dystrophic Onychomycosis Caused by Aspergillus clavatus Resistant to Antifungal Drugs. Mycopathologia. 2016 Apr;181(3-4):273–7. doi: 10.1007/s11046-015-9954-6.
    参考文献:10.1016/j.bmc.2018.04.056
    摘要:Ouf SA, Gomha SM, Eweis M, Ouf AS, Sharawy IA. Efficiency of newly prepared thiazole derivatives against some cutaneous fungi. Bioorg Med Chem. 2018 Jul 23;26(12):3287–95. doi: 10.1016/j.bmc.2018.04.056.
    摘要:Oka H, Niwano Y, Ohmi T, Tanaka T, Uchida M, Yamaguchi H. Therapeutic efficacy of latoconazole in formulations of clinical use on experimental dermatophytosis in guinea pigs. Arzneimittelforschung. 1992 Mar;42(3):345–9.
    参考文献:10.2165/00126839-199901020-00010
    摘要:Coleman SG, Brooke G. Antifungal agents. Summary and table. Drugs R D. 1999 Feb;1(2):161–4. doi: 10.2165/00126839-199901020-00010.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知